P/B
2,3
Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
$712.3M
Market Cap • 10/6/2026
2002
(24 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
0,9
P/EBITDA
1,8
P/OCF
2,2
P/FCF
2,2
P/E
17,6
BVPS
9,6
EPS
1,3
Market Cap
Market Cap
712,3M
EV
1,8B
EV/Revenue
2,2
EV/EBITDA
4,6
EV/EBIT
11,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
1,8%
Total Yield
1,8%
Payout
0%
Retained Earnings
-101,7M
Profitability
Gross Margin
60%
EBITDA Margin
48,4%
EBIT Margin
19,5%
Net Margin
5,9%
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0,2%
Capex/D&A
0,7%
Capex/OCF
0,5%
SBC/OCF
13,6%
% PPE
0,7%
% Goodwill
8,9%
ROE
17,6%
ROIC
7,2%
Growth
CAGR Revenue 5Y
19,9%
CAGR Op. Income 5Y
16,9%
CAGR Net Income 5Y
-14,8%
CAGR EPS 5Y
-14,5%
CAGR OCF 5Y
25,3%
Leverage
N.D./EBITDA
2,8
Debt/Equity
0%
Current Ratio
1
Quick Ratio
0,7
Interest Coverage
206%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!